Terms ending in 2037
Every in-force patent on ImmunoGen, Inc.'s record whose computed term ends in 2037, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 11,033,564 | Therapeutic Combinations Comprising ANTI-FOLR1 Immunoconjugates In force · High confidence | ImmunoGen, Inc. | In force | High confidence | |
| US 11,278,628 | Pharmaceutical Formulations and Methods of Use Thereof In force · High confidence | ImmunoGen, Inc. | In force | High confidence | |
| US 10,287,256 | Selective Sulfonation of Benzodiazepine Derivatives In force · High confidence | ImmunoGen, Inc. | In force | High confidence | |
| US 10,494,348 | Selective Sulfonation of Benzodiazepine Derivatives In force · High confidence | ImmunoGen, Inc. | In force | High confidence | |
| US 10,822,313 | Selective Sulfonation of Benzodiazepine Derivatives In force · Medium confidence | ImmunoGen, Inc. | In force | Medium confidence | |
| US 10,898,579 | Conjugates of Cysteine Engineered Antibodies In force · High confidence | ImmunoGen, Inc. | In force | High confidence |
6 of 6 patents shown. Soonest term end first, then patent number.
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.